Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue SUPPL. 2, 2008, Pages

  Kawai, Takashi ^a,c   Yamagishi, Tetsuya ^a   Yagi, Kenji ^a   Kataoka, Mikinori ^a   Kawakami, Kohei ^a   Sofuni, Atsushi ^a   Itoi, Takao ^a   Sakai, Yoshihiro ^a   Moriyasu, Fuminori ^a   Osaka, Yoshiaki ^a   Takagi, Yu ^a   Aoki, Tatsuya ^a   Rimbara, Emiko ^b   Noguchi, Norihisa ^b   Sasatsu, Masanori ^b  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^c NONE

Author keywords

Clarithromycin (CAM) resistant; Feces; Tailored eradication

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; LANSOPRAZOLE; METRONIDAZOLE; RABEPRAZOLE;

ADULT; AGED; ANGULAR CHEILOSIS; ANTIBIOTIC SENSITIVITY; BLOATING; CHEILOSIS; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DNA SEQUENCE; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT OUTCOME;

EID: 57449109993     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05408.x     Document Type: Conference Paper

References (26)

1. Asaka M, Sugiyama T, Kato M et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001 6 : 254 61.
2. Kawai T, Kawakami K, Kataoka M et al. The effectiveness of packaged medicine in eradication therapy of Helicobacter pylori in Japan. J Clin. Biochem. Nutr. 2006 38 : 73 6.
3. Hokari K, Sugiyama T, Kato M et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment. Pharmacol. Ther. 2001 15 : 1479 84.
4. Perri F, Villani MR, Festa V et al. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment. Pharmacol. Ther. 2001 15 : 1023 9.
5. Kamada T, Haruma K, Komoto K et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin and clarithromycin. Helicobacter. 1999 4 : 204 10.
6. Kamada T, Haruma K, Miyoshi E et al. Cetraxate, a mucosal protective agent, combined with omeprazole, amoxicillin and clarithromycin increases the eradication rate of Helicobacter pylori in smoker. Aliment. Pharmacol. Ther. 2000 14 : 1089 94.
7. Furuta T, Shirai N, Takashima M et al. Effect of genotypic difference in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 2001 69 : 158 68.
8. Poon SK, Chang CS, Su J et al. Primary resistance to antibiotics and its clinical impact the efficacy of Helicobacter pylori lansoprazole-based triple therapy. Aliment. Pharmacol. Ther. 2002 16 : 291 6.
9. Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N. Clarithromycin resistance, but not CYP2C19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for the cure of H. pylori infection. Dig. Dis. Sci. 2001 46 : 2445 50.
10. Rimbara E, Noguchi N, Tanabe M, Kawai T, Matsumoto Y, Sasatsu M. Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001. Clin. Microbiol. Infect. 2005 11 : 307 11.
11. Murakami K, Kato M, Kato S et al. Report of surveillance of drug resistant Helicobacter pylori in Japan 2002. Helicobacter Res. 2004 6 : 42 7.
12. Nasu M, Kobayashi T. Report of surveillance of drug resistant Helicobacter pylori in Japan 2004. Helicobacter Res. 2006 10 : 524 7.
13. Malfertheiner P, Megraud F, O'Morain C et al. Current European concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56.
14. Rimbara E, Norihisa N, Yamaguchi T, Narui K, Kawai T, Sasatsu M. Development of highly sensitive method for detection of clarithromicin- resisitant Helicobacter pylori from human feces. Curr. Microbiol. 2005 51 : 1 5.
15. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 1994 269 : 15419 22.
16. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of new genetic defect responsible for the polymorphism of (S) -mephenytoin metabolism in Japanese. Mol Pharmacol. 1994 46 : 594 8.
17. Hoshiya S, Watanabe K, Tokunaga K et al. Relationship between eradication therapy and clarithmycin-resistant Helicobacter pylori in Japan. J. Gastroenterol. 2000 35 : 10 14.
18. Kawai T, Kawakami K, Kudo T et al. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan. Hepatogastroenterology 2007 54 : 649 54.
19. Isomoto H, Inoue K, Furuso H et al. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2003 18 : 101 7.
20. Murakami K, Sato R, Okimoto T et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther. 2003 17 : 119 23.
21. Kawai T, Kawakami K, Kataoka M et al. Comparison of efficacies of dual therapy and triple therapy using rabeprazole in second-line eradication of Helicobacter pylori in Japan. Aliment. Pharmacol. Ther. 2006 24 (Suppl. 16 22.
22. Debets-Ossenkopp YJ, Sparrius M, Kuster JG et al. Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol. Lett. 1996 142 : 37 42.
23. Versalvoic J, Shortrige D, Kriber K et al. Mutatron in 235 rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob. Agent Chemother. 1996 40 : 477 80.
24. Russman H, Schmidt AF, Adler K, Aust. D, Fischer A, Koletzko S. Detection of Helicobacter pylori in paraffin-embedded and in shock-frozen gastric biopsy samples by fluorescent in situ hybridization. J. Clin. Microbiol. 2003 41 : 813 15.
25. Maeda S, Yoshida H, Matsunaga H et al. Detection of clarithromycin- resistant Helicobacter pylori strains by a preferential homoduplex formation assay. J. Clin. Microbiol. 2000 38 : 210 14.
26. Schabereiter-Gurtner C, Hirshl AM, Dragosics B et al. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. J. Clin. Microbiol. 2004 42 : 4512 18.